Advances in treatment for women with advanced breast cancer (ABC) have led to improvements in survival. Although the condition remains incurable, treatment goals focus on stabilizing disease, prolonging life, and maintaining patient quality of life. Hormone receptor-positive (HR þ ) subtypes constitute the majority of breast cancers, and an increasing number of effective endocrine therapies are available. Although practice guidelines provide important recommendations and principles for treatment selection, the choice of specific agents from among existing options should be customized to the individual based on patient and disease characteristics, as well as the nature and duration of response to previous treatments. This review examines endocrine and endocrine-based options, including combinations with targeted agents, for HR þ and human epidermal growth factor receptor 2-negative (HER2 À ) ABC. It also elaborates on the factors that enter into treatment decision-making, using patient case examples to illustrate how ABC can present and the clinical issues involved in treatment selection. Case examples are included to provide evidence for the clinical scenarios of de novo HR þ /HER2 À ABC and progression during adjuvant treatment for early breast cancer.
Introduction
Despite advances in medicine and drug development, advanced breast cancer (ABC) remains incurable and represents an unmet medical need. Although overall mortality rates have declined, the median survival for women with ABC is approximately 2 to 3 years, with a 5-year survival rate of 25% or less, depending on the database cited and the time during which the data were gathered. [1] [2] [3] [4] Estrogen receptor-positive (ER þ ) tumors represent up to 80% of all breast cancers. [5] [6] [7] Among patients in the United States with ABC, approximately 60% to 75% have hormone receptor-positive (HR þ ) (ie, ER þ and/or progesterone receptor-positive [PgR þ ]) disease. 8 The incidence of HR þ tumors tends to increase with age and vary with ethnicity. 7, 9 This review examines available endocrine and endocrine-based treatment options for the management of HR þ , human epidermal growth factor receptor 2-negative (HER2 À ) ABC, including endocrine therapy (ET) and targeted therapies, as well as newly investigated combinations and monotherapies. It also elaborates on factors that enter into treatment decision-making, using patient case examples to illustrate how ABC can present and the clinical issues involved in treatment selection. Case examples are included to provide evidence for the clinical scenarios of de novo ABC and recurrence during adjuvant treatment for early breast cancer.
Considerations in Choosing Treatment
Advances in endocrine-based therapeutics have improved survival for women with HR þ ABC. [10] [11] [12] [13] And because women with HR þ breast cancer are living longer, patient quality of life has come to the forefront of clinical decision-making. 12 The following includes several factors that should be considered when selecting from among available therapies for women with HR þ ABC.
Disease burden (eg, volume and the number of metastases); HER2 status.
In addition, the following patient factors also warrant consideration:
Comorbidities; Patient performance status; Patient preferences; Patient access to drug coverage.
Several treatment options are available for women with HR þ ABC. The selective ER modulator (SERM) tamoxifen is one of the earliest forms of ET used in the treatment of HR þ disease and is the most firmly established ET used as adjuvant therapy for both preand postmenopausal women. 12, 17 In premenopausal women, ovarian ablation or treatment with luteinizing hormone-releasing hormone analogues such as goserelin and leuprolide 11 may be used to suppress ovarian function. 12, 13 For postmenopausal women, the nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole, 18, 19 the steroidal AI exemestane, 20 and the selective ER degrader (SERD) fulvestrant 21 are established, approved, and effective therapeutic options. Development of resistance to ET in HR þ ABC is common, and most patients experience disease progression. 22, 23 However, the mechanisms underlying disease progression and the development of resistance to ET are complex and not fully understood, but likely resistance pathways differ for AIs versus SERMs/SERDs. In recent years, greater understanding of the molecular pathways of resistance has led to increased investigation of combinations that include ET and targeted agents, such as everolimus, a mammalian target of rapamycin (mTOR) inhibitor, and palbociclib, a cyclin-dependent kinase (CDK) inhibitor. Although these novel combinations may provide additional therapeutic options for women with ET-resistant disease, tradeoffs may include increased toxicity and added cost. 22, 23 Studies suggest that patients with HR þ metastatic disease whose disease has progressed during first-line ET might still respond to different types of ET in the second line. 24, 25 These observations support that well-tolerated, sequential ET may slow progression in HR þ ABC and potentially delay the need for chemotherapy. 12, 13 Indeed, this approach is recommended in clinical practice guidelines. 12, 26 The optimal sequencing of ETs, however, remains unclear, and decisions regarding sequencing approaches may be confounded by clinical variables such as menopausal status or previous treatments. 12, 27 Careful consideration of factors such as prior ET and the time to progression on that treatment (ie, early relapse, 12 months may be indicative of resistance; > 12 months may suggest endocrine sensitivity), mechanism of action and the potential for crossresistance, site of metastasis, whether the patient demonstrated symptoms, and the current clinical evidence are paramount. 14 
Overview of Treatment Options in HR-positive ABC: Endocrine Therapies and Targeted Agents
An overview of currently available ETs and targeted agents is presented in Table 1 . [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Data from key phase III studies of endocrine and endocrine-based therapies for ABC are presented in Table 2 . 
AIs
AIs, which include anastrozole, letrozole, and exemestane, decrease the amount of estrogen in postmenopausal women by blocking the enzyme aromatase that converts androgens to estrogen in peripheral tissue, including breast tumor cells. 66 Anastrozole and letrozole are nonsteroidal AIs that bind reversibly to aromatase, inhibiting the enzyme. 66 Exemestane is a steroidal AI and analogue of the endogenous aromatase substrate androstenedione, whose metabolites bind irreversibly to aromatase, causing permanent inactivation of the enzyme. [67] [68] [69] [70] Prior to the approval of palbociclib, single-agent ET was the mainstay therapy for women with HR þ , recurrent disease in the metastatic setting. 11 AIs remain an important option in first-line therapy for postmenopausal women with HR þ ABC and are generally well-tolerated. 52, 71, 72 AEs associated with AI monotherapy may include musculoskeletal symptoms, hot flashes, vaginal dryness, and an increased risk of bone fracture. 12, [32] [33] [34] Direct comparative studies of the 3 AIs in first-line therapy of ABC have not been conducted, although results across studies suggest similar efficacy and tolerability. The current National Comprehensive Cancer Network guidelines recommend ovarian suppression plus ET for treating premenopausal women with HR þ ABC , which could then include an AI.
12
Based on using a dual-blockade approach, combining ETs with different mechanisms of action, the combination of a SERM with an AI was investigated to assess clinical benefit over either therapy alone. Early studies with fadrozole and vorozole did not consistently provide additional anti-tumor activity when used in combination with tamoxifen. 73, 74 Later preclinical studies reported that letrozole alone was superior to tamoxifen, and added benefit was not evident with the combination treatment. The findings of studies conducted with anastrozole in combination with tamoxifen were similar to those with letrozole. 75 
SERD
Fulvestrant is a SERD 35 In the advanced breast cancer studies, the most common (occurring with an incidence of > 10%) AEs occurring in women taking anastrozole included hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis, and peripheral edema. The most common adverse reactions (> 20%) were hot flashes, arthralgia, flushing, asthenia, edema, headache, dizziness, hypercholesterolemia, sweating increased, bone pain, and musculoskeletal.
Steroidal AIs
Exemestane 34 Adjuvant treatment of postmenopausal women with ER þ early-stage breast cancer who have received 2 to 3 years of tamoxifen and are switched to exemestane for completion of a total of 5 consecutive years of adjuvant hormonal therapy The treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy Advanced breast cancer: Most common AEs were mild to moderate and included hot flashes, nausea, fatigue, increased sweating, and increased appetite.
treatment of HR
þ metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy, and for treatment of HR þ /HER2 À advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after ET (discussed below). 35 The most frequent AEs observed with fulvestrant (occurring with a frequency of ! 5% of patients) include injection-site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremities, hot flashes, vomiting, anorexia, asthenia, musculoskeletal pain, cough, dyspnea, and constipation. 35, [79] [80] [81] À advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
The most common adverse reactions occurring in ! 5% of patients receiving fulvestrant 500 mg were injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flashes, vomiting, anorexia, asthenia, musculoskeletal pain, cough, dyspnea, and constipation. Increased hepatic enzymes (ALT, AST, ALP) occurred in > 15% of fulvestrant patients and were not dose-dependent.
Targeted agents HER2-targeted antibody

Trastuzumab 36
Approved in combination with paclitaxel for first-line treatment of HER2-overexpressing MBC, and as a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease MBC: Most common AEs (incidence ! 10%) were fever, chills, headache, infection, congestive heart failure, insomnia, cough, and rash. Most common AEs (incidence ! 10%) were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy, decreased appetite, mucosal inflammation, asthenia, vomiting, anemia, peripheral edema, myalgia, nail disorder, headache, stomatitis, pyrexia, dysgeusia, leukopenia, upper respiratory tract infection, arthralgia, constipation, increased lacrimation, dyspnea, pruritus, febrile neutropenia, insomnia, dizziness, nasopharyngitis, dry skin.
mTOR inhibitor
Everolimus 38
Postmenopausal women with advanced HR þ /HER2 À breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole Most common AEs (incidence ! 10%) were stomatitis, infections, rash, diarrhea, fatigue, decreased appetite, nausea, cough, dysgeusia, weight decreased, arthralgia, headache, dyspnea, edema peripheral, pneumonitis, vomiting, epistaxis, pyrexia, constipation, hyperglycemia, back pain, insomnia, pruritus, asthenia, dry mouth, and alopecia. Most common adverse reactions (incidence ! 10%) were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, headache, diarrhea, thrombocytopenia, constipation, alopecia, vomiting, rash, and decreased appetite. 
CDK4/6 inhibitor
/HER2
À advanced or MBC.
Most common adverse reactions (incidence ! 20%) are neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, constipation, headache, and back pain.
Abbreviations: ABC ¼ advanced breast cancer; AE ¼ adverse event; AI ¼ aromatase inhibitor; ALP ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; CDK ¼ cyclin-dependent kinase; ER ¼ estrogen receptor; HER2 ¼ human epidermal growth receptor 2; HR ¼ hormone receptor; MBC ¼ metastatic breast cancer. a Note that AE rates should not be compared across studies because these were not head-to-head studies and rates selected as "most common" differed as well. b Possible effect of decreased estrogen. Treatments for HR þ /HER2 À ABC may also include the targeted inhibition of other pathways involved in the promotion of tumor cell proliferation, such as the mTOR 82 and CDK4/6 signaling pathways. [83] [84] [85] Abnormal signaling through the phosphatidylinositol 3-kinase-Akt-mTOR pathway may be a mechanism of resistance to ET, suggesting the potential for mTOR-targeted therapies in patients with endocrine-resistant, HR þ ABC. 52 Everolimus, a derivative of sirolimus (formerly rapamycin), inhibits mTOR signaling through allosteric binding to mTORC1. 86, 87 Preclinical studies have shown that the use of everolimus in combination with AIs yields synergistic inhibition of cell proliferation and induction of apoptosis. 88 Everolimus is FDA-approved in combination with exemestane for treatment of postmenopausal women with HR þ / HER2
À ABC after failure of treatment with letrozole or anastrozole. 38, 52 AEs associated with everolimus are consistent with those observed for other rapamycin analogues and include stomatitis, infections, rash, fatigue and asthenia, diarrhea, edema, abdominal pain, nausea, cough, headache, and decreased appetite. 38, 52, 89 It is well-recognized that cell-cycle progression is dysregulated in certain molecular subtypes of breast cancer. [83] [84] [85] The first FDAapproved CDK4/6 inhibitor, palbociclib, 90 blocks progression from G1 into S phase of the cell cycle and represents a new pathway to target in HR þ ABC. 83 It is approved for use in HR þ /HER2
À ABC in combination with letrozole for the first-line treatment of postmenopausal women, and in combination with fulvestrant for disease progression following ET in both pre-and postmenopausal women. 39 The most common adverse reactions observed in the pivotal studies (incidence ! 10%) were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, headache, diarrhea, thrombocytopenia, constipation, alopecia, vomiting, rash, and decreased appetite. 39 In March 2017, ribociclib (LEE011) was granted FDA approval as first-line treatment for HR þ /HER2 À ABC in combination with any AI. 40 In the planned interim analysis of the Mammary ONcology Assessment of LEE011's Efficacy and SAfety-2 (MONALEESA-2) study, which is evaluating ribociclib (600 mg) in combination with letrozole (2.5 mg) compared with letrozole plus placebo in postmenopausal women with HR þ /HER2 À recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease, common grade 3/4 AEs were neutropenia, leukopenia, hypertension, elevated alanine aminotransferase, lymphopenia, and elevated aspartate aminotransferase. 56 An additional CDK4/6 inhibitor, abemaciclib (LY2835219), is under evaluation and may become a future option for treatment. In June 2016, the first interim results were reported from the phase II, single-arm MONARCH given orally every 12 hours continuously until progression, along with anastrozole 1 mg or letrozole 2.5 mg once daily at the investigator's discretion, with assessments every 28 days. 93 
ESR Mutation
The emergence of ESR1 mutations occurs primarily in ABC after exposure to AIs, 94 resulting in dose-dependent changes in responsiveness to endocrine agents. [95] [96] [97] [98] Retrospective analysis of baseline plasma samples from patients enrolled in the phase III Study of Faslodex vs Exemestane with/ without Arimidex (SoFEA) study, which evaluated fulvestrant (500 mg intramuscularly on day 1, followed by 250 mg on days 15 and 29, then every 28 days) with placebo or anastrozole (1 mg) versus exemestane (25 mg) in patients with prior sensitivity to AIs, suggests that the presence of ESR1 mutations may impart sensitivity to fulvestrant. Plasma samples from 161 (22.4%) of 723 patients were analysed for ESR1 mutations. Of these, 63 (39%) had ESR1 mutations, and among these, 49.1% (27 of 55) were polyclonal. Patients with ESR1 mutations had improved progression-free survival (PFS) after receiving fulvestrant compared with exemestane (hazard ratio [HR], 0.52; 95% CI, 0.30-0.92; P ¼ .02). However, patients with wild-type ESR1 had similar PFS regardless of treatment (HR, 1.07; 95% CI, 0.68-1.67; P ¼ .77). 99 In the phase III Palbociclib Ongoing Trials in the Management of Breast Cancer-3 (PALOMA-3) study, conducted in patients with HER2
À ABC who had progressed on previous ET, the prevalence of ESR1 mutations was 25.3% (91 of 360). Among those, 28.6% (26 of 91) were polyclonal, with mutations associated with acquired resistance to prior AIs. Improved PFS was observed for the fulvestrant plus palbociclib arm versus the fulvestrant plus placebo arm in both ESR1-mutant (HR, 0.43; 95% CI, 0.25-0.74; P ¼ .002) and ESR1-wild-type patients (HR, 0.49; 95% CI, 0.35-0.70; P < .001). 99 In the Breast Cancer Trials of Oral Everolimus-2 study (BOLERO-2), an international, double-blind, randomized, phase III study comparing everolimus plus exemestane to placebo plus exemestane in Patients with the D538G mutation demonstrated a similar PFS benefit (HR, 0.34; 95% CI, 0.02-0.57) from the addition of everolimus to exemestane as did those without D538G or Y537S mutations. 98 These studies indicate that ESR1 mutations are prevalent in ER þ , AI-treated ABC. Both Y537S and D538G mutations are associated with more aggressive disease biology.
Case Studies
The following patient-case scenarios provide opportunities to examine factors that may impact therapeutic strategies for postmenopausal patients with HR þ ABC. Selected treatment recommendations based on available data and the clinical experience of the authors are presented in Figure 1 . For any postmenopausal patient with HR þ disease and bone and/or soft tissue or asymptomatic visceral metastases, the National Comprehensive Cancer Network Clinical Guidelines in Oncology for breast cancer currently recommend 3 lines of ET before considering cytotoxic chemotherapy. 12 Optimal sequencing has not yet been determined 12, 27 and is subject to change with the emergence of new agents.
Case Study 1: De Novo ABC
A 67-year-old woman with no history of breast cancer presented with a 3-cm nodule in the left breast and hip pain that had not resolved despite treatment with nonsteroidal anti-inflammatory drugs. Workup revealed bone metastases including the pelvis and low-volume malignant pleural effusion in the right lung. Biopsy and subsequent pathology findings revealed ER þ , PgR þ , HER2 À ABC.
The overall rate of patients with HR þ ABC who have not received prior ET is reported to be 3% to 6%, 100 and other data suggest that the rate may be higher. The variation in rates may be subject to regional differences in reporting, which are affected by various factors, such as affluence and insurance coverage, that also impact patients' ability to seek care early in their disease. 101, 102 This case provides clinical guidance for first-line options.
Options for Monotherapy. Recommended monotherapy options for postmenopausal patients with HR
þ ABC who are ET-naive or have had no ET for more than 12 months, include a SERM (eg, tamoxifen) or AI (letrozole, exemestane, or anastrozole). 12, 26 However, emerging data based on the Fulvestrant and anastrozole compared in hormonal therapy naïve advancedbreast cancer (FALCON) study (discussed below) provide evidence for fulvestrant as a potential new option for endocrine-naive patients. 103 Comparative studies of tamoxifen versus AIs support the first line use of third-generation AIs in ABC. The outcomes of several phase III studies comparing anastrozole, letrozole, or exemestane with tamoxifen as first-line therapy in postmenopausal women with advanced endocrine-sensitive breast cancer indicate that AIs offer a modest, but statistically significant, benefit in comparison with tamoxifen. 12, [41] [42] [43] [44] 46 At this time, no head-to-head comparison studies of third-generation AIs in the metastatic setting have been conducted to determine the superiority of one agent over another. 27 Clinical Studies of Fulvestrant First-line Monotherapy. Fulvestrant has been evaluated thoroughly in clinical studies as a single agent, in first-and second-line therapy, and in combination with other agents. 104 Although not currently approved for first-line treatment, data regarding the use of fulvestrant 500 mg in the ET-naive setting are available. The findings from the FIRST study led to the phase III confirmatory FALCON study that also compared fulvestrant with anastrozole for first-line treatment of ET-naive patients with HR þ locally advanced or ABC. 103 In total, 462 patients were randomized to receive fulvestrant 500 mg (n ¼ 230) or anastrozole 1 mg (n ¼ 232). The primary endpoint was met as demonstrated by a significant improvement in PFS with fulvestrant versus anastrozole (HR, 0.797; 95% CI, 0.637-0.999; P ¼ .049; median PFS, 16.6 vs. 13.8 months, respectively). 103 Although OS data were not yet mature at the time of publication, the PFS data suggest that fulvestrant may soon become a treatment option in the ET-naive setting. The confirmatory phase III study (PALOMA-2) evaluated palbociclib 125 mg/day in 3-week-on, 1-week-off treatment cycles plus letrozole 2.5 mg/day continuously, compared with letrozole alone every 28 days in 666 postmenopausal patients without prior systemic therapy for ABC. As of February 2016, 331 PFS events were reported with a median PFS for the combination of palbociclib and letrozole of 24.8 versus 14.5 months for letrozole alone (HR, 0.58; 95% CI, 0.46-0.72; P < .001). The ORR was significantly higher in the palbociclib plus letrozole arm (42.1% vs. 34.7%; P ¼ .031) than in the letrozole-alone arm. In patients with measureable disease, the ORR was 55.3% and 44.4% for the palbociclib plus letrozole and letrozole-alone arms, respectively (P ¼ .013). OS was not reported because the data were immature. , lymph-nodeenegative breast cancer was prescribed a 5-year course of anastrozole after an initial lumpectomy followed by radiation. During her fourth year of anastrozole treatment, she was diagnosed with multiple bone metastases, but no evidence of visceral disease. A biopsy confirmed that the metastasis had the same biologic profile as the index tumor.
Sequencing Considerations for Progression During or After Endocrine Therapy. When progression occurs after ET, as is typical of ABC, it is reasonable to select an ET with a different mechanism of action (eg, fulvestrant after tamoxifen), an agent of different chemical class (eg, a steroidal AI such as exemestane after a nonsteroidal AI such as anastrozole), or combination therapy with targeted agents (eg, palbociclib plus fulvestrant or exemestane with everolimus). 26 Other options in this setting include androgens and high-dose ethinyl estradiol. 12 In vitro research suggests that primary resistance may emerge from heightened tumor sensitivity to low estrogen levels in situations of prolonged estrogen depletion. 108 Therefore, fulvestrant, which promotes degradation of the ER, and thereby complete blockade of ER signaling, may be an option in AI-resistant patients. 79 The combination of palbociclib and fulvestrant has received FDA approval based on the findings of the phase III study, PALOMA-3 ( Table 2 ). This study demonstrated that the combination of palbociclib and fulvestrant resulted in significantly longer PFS than treatment with fulvestrant alone (9.5 vs. 4.6 months, respectively; HR, 0.46; 95% CI, 0.36-0.59; P < .001). 39, 54 The AE profile of the combination regimen was consistent with previously reported data for each agent. The most common AEs of all grades and rates of study discontinuation in the palbociclib/fulvestrant group were consistent with the CDK4/6 toxicity profile. 55 Quality of life measures included the European Organisation for Research and Treatment of Cancer QLQ-C30 and its breast cancer module, QLQ-BR23. Overall global quality of life was maintained over the treatment period in the palbociclib/fulvestrant group compared with fulvestrant monotherapy. 55 Earlier phase III, randomized, clinical studies that led to the approval of fulvestrant demonstrated that the 250 mg dose was as effective as anastrozole in tamoxifen-resistant ABC. 21, 45 Because fulvestrant degrades the ER in a dose-dependent manner, it was hypothesized that a higher dosage might provide superior benefit, 109 leading to the phase III Comparison of FASLODEX in Recurrent or Metastatic Breast Cancer (CONFIRM) study. This study compared the safety and efficacy of fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with ER þ ABC who experienced progression after prior ET. The study demonstrated the superior efficacy of fulvestrant 500 mg, and this dosage has since been approved by the FDA. PFS was significantly longer for fulvestrant 500 mg over 250 mg (HR, 0.80; 95% CI, 0.68-0.94; P ¼ .006), representing a 20% reduction in the risk of disease progression. Fulvestrant 500 mg was also associated with a clinically relevant 4.1-month increase in median OS, and a 19% reduction in risk of death compared with fulvestrant 250 mg. 48, 49 Toxicity was generally similar between the 2 doses. 35, 48, 49 Among AIs, exemestane was shown to provide clinical benefit in a phase II clinical study in patients with ABC who had failed up to 3 lines of nonsteroidal AIs. 20 In this open-label, uncontrolled, phase II study, exemestane 25 mg was associated with an objective response of 6.6% (95% CI, 3.8%-10.6%) and an overall success rate of 24.3% (95% CI, 19.0%-30.2%); the median durations of the objective response and overall success were 58.4 and 37.0 weeks, respectively. 20 In a phase II, sequential, 2-stage, uncontrolled study of second-line exemestane in HR þ or HR-unknown patients (n ¼ 50) who had been treated in the first line with anastrozole, exemestane demonstrated clinical benefit. The clinical benefit rate (ie, complete response þ partial response þ stable disease > 6 months) for anastrozole and exemestane was 73% and 44%, respectively. 110 For patients who may have already received first-line antiestrogen therapy, letrozole has also been shown to have clinical benefit as second-line therapy in ABC. 19, 111 The combination of the mTOR inhibitor everolimus with exemestane has also been approved for the treatment of postmenopausal women with advanced HR þ /HER2 À breast cancer in combination with exemestane after treatment failure with letrozole or anastrozole. 38 10; log-rank P ¼ .14). 113, 114 There were, however, more AEs reported in the combination arm, including stomatitis, anemia, dyspnea, hyperglycemia, fatigue, and pneumonitis, and these should be taken into account when selecting therapy.
52,113
Supportive Treatment
Supportive therapy plays an important role in the management of patients with ABC. 12 For example, bisphosphonates and denosumab, in combination with calcium and vitamin D supplementation, are well-established treatments that may be considered to reduce the risk of skeletal-related events in patients with bone metastases. 12, 115 Management strategies for the other potential side effects of treatment (mucositis, stomatitis, injection-site reactions, nausea, and musculoskeletal pain) have been covered in detail elsewhere in the literature.
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Summary and Conclusions
The increase in the number of options for ET and endocrine-based therapy is challenging traditional approaches to therapy sequencing for patients with HR þ ABC. Strategies are largely based on previous ET exposure, HR and HER2 status, menopausal status, and tolerability of therapy. Although current treatments for HR þ ABC are not curative, clinical evidence indicates that ET can slow disease progression with a low risk of significant AEs. Use of targeted agents to inhibit intracellular pathways important for cell proliferation can significantly enhance the efficacy of currently available endocrine interventions to stabilize disease and delay progression. However, such treatments are associated with a higher incidence of AEs than ET alone and have not yet confirmed an OS benefit.
